Biomark Diagnostics (STU:20B) LT-Debt-to-Total-Asset: 0.23 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:20B Biomark Diagnostics Inc STU:20B
27 GF Score
Price €0.32
! 4 Warning Signs
View Full Analysis

What is Biomark Diagnostics LT-Debt-to-Total-Asset?

Biomark Diagnostics STU:20B 27 LT-Debt-to-Total-Asset is 0.23 as of Mar. 2026. GuruFocus rates STU:20B with a GF Score™ of 27/100. The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Biomark Diagnostics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.23.

Biomark Diagnostics's long-term debt to total assets ratio increased from Mar. 2025 (0.05) to Mar. 2026 (0.23). It may suggest that Biomark Diagnostics is progressively becoming more dependent on debt to grow their business.

Biomark Diagnostics  (STU:20B) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Biomark Diagnostics LT-Debt-to-Total-Asset Related Terms

Biomark Diagnostics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Biomark Diagnostics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomark Diagnostics LT-Debt-to-Total-Asset Chart

Biomark Diagnostics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.41 0.30 0.42 0.05 0.23

Biomark Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.04 0.01 0.18 0.23
STU:20B
27GF Score
Biomark Diagnostics Inc STU:20B
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomark Diagnostics LT-Debt-to-Total-Asset Calculation

Biomark Diagnostics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )/Total Assets (A: Mar. 2026 )
=0.272/1.173
=0.23

Biomark Diagnostics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=0.272/1.173
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.23 mean?
Biomark Diagnostics (STU:20B) has a LT-Debt-to-Total-Asset of 0.23 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Biomark Diagnostics and its competitors.
Is Biomark Diagnostics' LT-Debt-to-Total-Asset too high?
Biomark Diagnostics' current LT-Debt-to-Total-Asset is 0.23. Overall, Biomark Diagnostics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Biomark Diagnostics' LT-Debt-to-Total-Asset compare to TMO and DHR?
Biomark Diagnostics' LT-Debt-to-Total-Asset of 0.23 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Diagnostics & Research company?
A good LT-Debt-to-Total-Asset depends on the Medical Diagnostics & Research industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Biomark Diagnostics and its competitors. Biomark Diagnostics's current LT-Debt-to-Total-Asset is 0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomark Diagnostics stock overvalued right now?
Biomark Diagnostics (STU:20B) has a current LT-Debt-to-Total-Asset of 0.23. The current LT-Debt-to-Total-Asset is 0.23. Biomark Diagnostics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Biomark Diagnostics (STU:20B), the current LT-Debt-to-Total-Asset is 0.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomark Diagnostics Business Description

Other Exchanges BMKDF:USABUX:Canada
Address 130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.
27GF Score

Get the complete analysis for STU:20B

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.32
Price